Related Experiment Videos
Bulbocapnine is not a selective DA1 receptor antagonist
The Journal of Pharmacy and Pharmacology
|May 1, 1986
Summary
Bulbocapnine equally inhibited both DA1 and DA2 dopamine receptor responses in dogs, indicating it is not a selective DA1 dopamine antagonist. This study clarifies bulbocapnine
Area of Science:
- Pharmacology
- Neuroscience
- Dopamine Receptor Research
Background:
- Dopamine receptors (DA1 and DA2) play critical roles in physiological processes.
- Understanding the selectivity of receptor antagonists is crucial for drug development and therapeutic applications.
Purpose of the Study:
- To investigate the antagonist activity of bulbocapnine on DA1 versus DA2 dopamine receptors.
- To determine if bulbocapnine exhibits selectivity for DA1 dopamine receptors under specific experimental conditions.
Main Methods:
- Simultaneous assessment of bulbocapnine's effects on DA1 and DA2 receptor-mediated responses in a pentobarbitone-anesthetized dog model.
- Utilized fenoldopam as a DA1 agonist (renal artery injection) and dipropyl dopamine or piribedil as DA2 agonists (femoral artery injection).
- Administered intravenous bulbocapnine at doses of 0.5 and 1 mg kg-1.
Main Results:
- Intravenous bulbocapnine administration resulted in nearly equal inhibition of both DA1 and DA2 dopamine receptor-mediated responses.
- No significant difference in the inhibitory effects on DA1 and DA2 receptors was observed at the tested doses.
Conclusions:
- Under the described experimental conditions, bulbocapnine does not act as a selective DA1 dopamine antagonist.
- Bulbocapnine exhibits non-selective antagonist activity at both DA1 and DA2 dopamine receptors.